Palatin Technologies, Inc. lead product candidate, Rekynda
09-Jan-17
$465 million
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Target:
Palatin Technologies, Inc. lead product candidate, Rekynda
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Acquiror:
AMAG Pharmaceuticals, Inc.
Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.